Veraxa Biotech AG - Post de-SPAC
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Veraxa Biotech AG - Post de-SPAC
Pharmaceutical Preparations, SIC 2834
Veraxa Biotech AG is a biotechnology enterprise focused on developing cancer therapeutics and biopharmaceutical treatments. The company focuses on the research, discovery, and development of oncology therapies utilizing proprietary platforms, including its Click Chemistry Antibody-Drug Conjugate (ADC) platforms and BiTAC platforms. Its development pipeline includes targeted therapeutic candidates such as VX-A901 for acute myeloid leukemia. Veraxa works with third-party business partners, research collaborators, and commercial organizations to advance and test its scientific programs and product candidates.
The company operates with international infrastructure primarily based in Europe. Veraxa maintains its principal executive offices in Zurich, Switzerland, and conducts corporate, research, and contact activities from an established location in Heidelberg, Germany. Veraxa Biotech AG is organized as a Swiss stock corporation operating across these corporate and scientific hubs.
Summary of the business section of Veraxa Biotech AG - Post de-SPAC's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Veraxa Biotech AG - Post de-SPAC
- Founded
- 2020
- Headquarters
- Zurich, Switzerland
- Address
- Talacker 35 8001
- Phone
- 41443858450
- Website
- veraxa.com
- Employees
- 41, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- V8
- Fiscal year ends
- December 31
- Auditor
- GRASSI & CO., CPAs, P.C, New York
Stock & identifiers
- Ticker
- VRXA
- Other tickers
- VRXAW
- Exchange
- Nasdaq
- IPO date
- Sep 30, 2024
- Shares outstanding
- 164M, Jun 10, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2079109
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christoph Rudiger Antz | Chief Executive Officer, Director | 5,000 |
| Raju Sudir Willener | Chief Financial Officer | – |
| Halem Carl von | Interim CFO | – |
| Heinz Schwer | Chief Business Officer | – |
| Torsten Georg Friedrich Buergermeister | Chief Financial Officer | – |
| Oliver Rolf Baumann | Director | 5,773,618 |
| Christoph Samuel Ziegler | Director | 7,932 |
| Marc Gruninger | Director | – |
| Warren Hosseinion | Director | 700,000 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 13, 2026 | Name change | Name changed from Veraxa Biotech Holding AG to Veraxa Biotech AG - Post de-SPAC |
| Jun 9, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 31, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |